Log in

NYSE:LLY - Eli Lilly And Co Stock Price, Forecast & News

$142.04
+0.04 (+0.03 %)
(As of 02/23/2020 02:28 PM ET)
Today's Range
$140.33
Now: $142.04
$142.65
50-Day Range
$131.72
MA: $139.96
$147.35
52-Week Range
$101.36
Now: $142.04
$147.87
Volume2.90 million shs
Average Volume3.29 million shs
Market Capitalization$135.84 billion
P/E Ratio16.21
Dividend Yield2.08%
Beta0.21
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP53245710
Phone317-276-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.32 billion
Cash Flow$7.08 per share
Book Value$2.82 per share

Profitability

Net Income$8.32 billion

Miscellaneous

Employees38,680
Market Cap$135.84 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.


Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly And Co's stock symbol?

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?

Eli Lilly And Co declared a quarterly dividend on Monday, December 16th. Stockholders of record on Friday, February 14th will be paid a dividend of $0.74 per share on Tuesday, March 10th. This represents a $2.96 annualized dividend and a dividend yield of 2.08%. The ex-dividend date of this dividend is Thursday, February 13th. This is an increase from Eli Lilly And Co's previous quarterly dividend of $0.65. View Eli Lilly And Co's Dividend History.

How were Eli Lilly And Co's earnings last quarter?

Eli Lilly And Co (NYSE:LLY) announced its quarterly earnings data on Thursday, January, 30th. The company reported $1.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.52 by $0.21. The business earned $6.11 billion during the quarter, compared to analyst estimates of $5.92 billion. Eli Lilly And Co had a net margin of 37.27% and a return on equity of 192.27%. The company's revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.33 EPS. View Eli Lilly And Co's Earnings History.

When is Eli Lilly And Co's next earnings date?

Eli Lilly And Co is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Eli Lilly And Co.

What guidance has Eli Lilly And Co issued on next quarter's earnings?

Eli Lilly And Co issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share guidance of $6.70-6.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.76. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.78 billion.

What price target have analysts set for LLY?

14 equities research analysts have issued 12-month price objectives for Eli Lilly And Co's shares. Their forecasts range from $117.49 to $165.00. On average, they anticipate Eli Lilly And Co's stock price to reach $137.95 in the next year. This suggests that the stock has a possible downside of 2.9%. View Analyst Price Targets for Eli Lilly And Co.

What is the consensus analysts' recommendation for Eli Lilly And Co?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eli Lilly And Co.

What are Wall Street analysts saying about Eli Lilly And Co stock?

Here are some recent quotes from research analysts about Eli Lilly And Co stock:
  • 1. According to Zacks Investment Research, "Lilly beat estimates for earnings in the first quarter.  However, Lilly lowered its sales guidance for 2019.  Revenue growth in 2019 is expected to be driven by higher demand for its newer drugs including Trulicity, Jardiance, Taltz, Verzenio and new migraine drug, Emgality as some older drugs like Cialis face generic competition. Lilly has made significant pipeline progress in the past year with several positive late-stage data readouts, multiple approvals and regulatory submissions. Lilly also added promising new pipeline assets through business development deals. The stock has outperformed the industry in the past year. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line." (5/21/2019)
  • 2. Cantor Fitzgerald analysts commented, ". EPS beat, we maintain our OW rating and 12- month PT of $143. We expect upward earnings revisions to move LLY’s shares higher. This should be driven by sales growth, margin expansion, and pipeline advancements." (4/30/2019)

Has Eli Lilly And Co been receiving favorable news coverage?

Media stories about LLY stock have trended very negative this week, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Eli Lilly And Co earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Eli Lilly And Co.

Are investors shorting Eli Lilly And Co?

Eli Lilly And Co saw a increase in short interest in January. As of January 31st, there was short interest totalling 12,980,000 shares, an increase of 14.8% from the January 15th total of 11,310,000 shares. Based on an average trading volume of 3,450,000 shares, the days-to-cover ratio is currently 3.8 days. Currently, 1.5% of the shares of the stock are short sold. View Eli Lilly And Co's Current Options Chain.

Who are some of Eli Lilly And Co's key competitors?

What other stocks do shareholders of Eli Lilly And Co own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly And Co investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AT&T (T), Intel (INTC), Bristol-Myers Squibb (BMY), Verizon Communications (VZ), Bank of America (BAC), JPMorgan Chase & Co. (JPM) and Cisco Systems (CSCO).

Who are Eli Lilly And Co's key executives?

Eli Lilly And Co's management team includes the folowing people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 51)
  • Mr. Joshua L. Smiley, Sr. VP & CFO (Age 49)
  • Dr. Daniel M. Skovronsky, Sr. VP & Chief Scientific Officer (Age 45)
  • Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 56)
  • Mr. Jeffrey N. Simmons, Sr. VP & Pres of Elanco Animal Health (Age 52)

Who are Eli Lilly And Co's major shareholders?

Eli Lilly And Co's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.93%), State Street Corp (3.87%), Capital International Investors (2.71%), FMR LLC (1.48%), Geode Capital Management LLC (1.29%) and Bank of New York Mellon Corp (0.85%). Company insiders that own Eli Lilly And Co stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, Daniel Skovronsky, David A Ricks, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.

Which major investors are selling Eli Lilly And Co stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., Investec Asset Management LTD, Alliancebernstein L.P., Janus Henderson Group PLC, LSV Asset Management, Assenagon Asset Management S.A., Massachusetts Financial Services Co. MA and AQR Capital Management LLC. Company insiders that have sold Eli Lilly And Co company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry. View Insider Buying and Selling for Eli Lilly And Co.

Which major investors are buying Eli Lilly And Co stock?

LLY stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Capital International Investors, FMR LLC, Amundi Pioneer Asset Management Inc., Franklin Resources Inc., CI Investments Inc., PGGM Investments and Robeco Institutional Asset Management B.V.. Company insiders that have bought Eli Lilly And Co stock in the last two years include Anne E White, Daniel Skovronsky, David A Ricks, Jackson P Tai and Joshua L Smiley. View Insider Buying and Selling for Eli Lilly And Co.

How do I buy shares of Eli Lilly And Co?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eli Lilly And Co's stock price today?

One share of LLY stock can currently be purchased for approximately $142.04.

How big of a company is Eli Lilly And Co?

Eli Lilly And Co has a market capitalization of $135.84 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis. Eli Lilly And Co employs 38,680 workers across the globe.View Additional Information About Eli Lilly And Co.

What is Eli Lilly And Co's official website?

The official website for Eli Lilly And Co is http://www.lilly.com/.

How can I contact Eli Lilly And Co?

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]


MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  994 (Vote Outperform)
Underperform Votes:  813 (Vote Underperform)
Total Votes:  1,807
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel